JAZZ — Jazz Pharmaceuticals plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1232524 ·
Ireland
Last close
$230.56
Market Cap
$14.47B
52W High
$243.32
52W Low
$177.58
ADV30
961,463
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,068,900,000 | 934,800,000 | 336,600,000 | 293,100,000 | 11,859,600,000 | 1,844,300,000 | 7,327,300,000 |
| Dec 2025 | 1,197,926,000 | 1,044,398,000 | 254,535,000 | 203,451,000 | 11,659,340,000 | 1,391,899,000 | 7,340,756,000 |
| Sep 2025 | 1,126,107,000 | 997,227,000 | 100,009,000 | 251,412,000 | 11,356,485,000 | 1,326,070,000 | 7,397,455,000 |
| Jun 2025 | 1,045,712,000 | 929,444,000 | 218,970,000 | -718,470,000 | 10,944,141,000 | 1,189,880,000 | 7,237,782,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,334,173,000
Investing CF
$-1,217,813,000
Financing CF
$-138,380,000
CapEx
$-190,552,000
Dividends Paid
—
Buybacks
$-150,001,000
EPS Diluted TTM
$-0.02
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$939,200,000
Inventory
$437,500,000
Receivables
$836,300,000
ST Investments
$1,030,000,000
EBIT TTM
$-37,603,000
Pretax Income TTM
$-218,848,000
Interest Exp TTM
$181,245,000
Analysts
17
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,438,686,208
EBITDA
$2,008,267,008
Free Cash Flow
$1,335,671,424
Enterprise Value
$17,008,584,704
Total Cash
$2,874,299,904
Total Debt
$5,416,900,096
Shares Out
62,742,820
Trailing EPS
$0.12
Book Value
$72.28
ROE
0.7%
ROA
6.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,267,586,000 | 517,622,000 | -356,148,000 | 11,659,340,000 | 7,340,756,000 | — | 1,355,773,000 |
| Dec 2024 | 4,068,950,000 | 726,630,000 | 560,120,000 | 12,012,257,000 | 7,918,501,000 | — | 1,395,908,000 |
| Dec 2023 | 3,834,204,000 | 597,580,000 | 414,832,000 | 11,393,359,000 | 7,656,362,000 | — | 1,092,007,000 |
| Dec 2022 | 3,659,374,000 | 512,268,000 | -224,060,000 | 10,835,255,000 | 7,749,521,000 | — | 1,271,977,000 |
TTM Snapshot
Revenues TTM
$3,805,876,000
NetIncome TTM
$289,394,000
OpCashFlow TTM
$0
Assets (Latest)
$12,012,257,000
Forward EPS
$25.63
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ASND | Ascendis Pharma A/S | $14.30B | $218.06 | — |
| GNMSF | GENMAB A/S | $15.29B | $249.00 | — |
| GMAB | GENMAB A/S | $15.40B | $25.08 | — |
| AXSM | Axsome Therapeutics, Inc. | $13.13B | $255.17 | — |
| BBIO | BridgeBio Pharma, Inc. | $13.08B | $66.80 | — |
News headlines (Yahoo Finance, 1h cache)
Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?
2026-06-15 21:48 · Yahoo
Pharmaceuticals Stocks Q1 Recap: Benchmarking Jazz Pharmaceuticals (NASDAQ:JAZZ)
2026-06-15 16:12 · Yahoo
Sector Update: Healthcare Stocks Softer Late Afternoon
2026-06-12 19:40 · Yahoo
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
2026-06-12 12:00 · Yahoo
New Xywav Data And FDA Ruling Put Jazz Valuation In Focus
2026-06-11 14:08 · Yahoo
3 Unpopular Stocks We Find Risky
2026-06-08 09:33 · Yahoo
Why Is Jazz (JAZZ) Up 1% Since Last Earnings Report?
2026-06-04 15:30 · Yahoo
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narco
2026-06-04 11:45 · Yahoo
Jazz Pharmaceuticals PLC (JAZZ): CBD-Based Epidiolex Drug Sales Up 15%
2026-05-31 12:15 · Yahoo
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
2026-05-30 17:56 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.